CNS, INC., ANNOUNCES FDA CLEARANCE TO MARKET
CNS, INC., ANNOUNCES FDA CLEARANCE TO MARKET MINNEAPOLIS, Nov. 11 /PRNewswire/ -- CNS, Inc. (NASDAQ: CNXS),
announced that the FDA has recently given clearance under the 510(k) process to market two new products: the Respi-Pak(TM) and RT-Pak(TM). Fred Brooks, president of CNS, stated that both new products will enhance the sale of sophisticated CNS sleep laboratory diagnostic equipment by offering the sleep technologist the ability to very accurately record three to eight channels of crucial respiratory and auxiliary physiological data during a sleep study.
Addition of these new physiological parameters, along with the currently recorded neurological, cardiac and other pulmonary parameters, will greatly enhance the diagnosis of sleep-associated problems such as excessive daytime sleepiness (EDS), inability to sleep (insomnia), chronic muscle and joint pain (fibromyalgia) and cessation of breathing (sleep apnea). CNS expects to begin shipments of the Respi-Pak and RT-Pak by December 1991. CNS, Inc., manufactures and markets on a global basis computer enhanced diagnostic equipment and consumable products for sleep disorder centers, operating rooms and home health care markets. -0- 11/11/91 /CONTACT: Fred Brooks, president of CNS, 612-474-7600/ (CNSX) CO: CNS, Inc. ST: Minnesota IN: MTC SU: PDT JS -- MN011 -- 2964 11/11/91 10:45 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 11, 1991|
|Previous Article:||CAMBRIDGE NEUROSCIENCE AWARDED ORPHAN DRUG STATUS FOR PRAMIRACETAM; PHASE III TRIALS TO BEGIN IN 1992|
|Next Article:||COKE CONSOLIDATED SIGNS LETTER OF INTENT OT ACQUIRE OPERATIONAL CONTROL OF SUNBELT COCA-COLA; WOULD BE SECOND LARGEST COKE BOTTLER IN U.S.|